You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盧寵茂:港大鼻噴式疫苗或明年首季完成一、二期臨床數據分析
阿思達克 11-30 18:09
醫務衛生局局長盧寵茂表示,政府一直歡迎科研機構在港研發疫苗,當局轄下醫療衛生研究基金自2020年4月已批出共2,950萬元撥款,支持兩所本地大學開展四個研發新冠疫苗相關的項目。 其中,港大醫學院微生物學系與廈門大學和北京萬泰生物合作,研發一款鼻噴式疫苗(衛活苗一號)獲基金資助約2,000萬元,以進行安全性一期和二期臨床測試;研究團隊現正收集免疫數據和分析,預計將於明年第一季完成。據悉,其後與疫苗相關的第三期臨床測試,由北京萬泰生物進行。基金會繼續適時分配資源,以支持本地科研及配合政府應對新冠疫情的工作。 他指,由政府主導的新冠疫苗接種計劃於去年二月展開,為市民提供科興和復必泰兩款新冠疫苗,並已獲認可作緊急使用;接種計劃推行至今,政府合共採購約946萬劑科興疫苗,以及約1,430萬劑復必泰疫苗,預計足夠為全港市民提供第一至第三劑疫苗,以及為部分人士提供第四劑加強劑疫苗。 他指,政府會密切留意第四劑疫苗的需求,並會在有需要時考慮增購,暫時未有計劃提供科興和復必泰疫苗以外的新冠疫苗認可作緊急使用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account